115 related articles for article (PubMed ID: 38426558)
21. Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2.
Hummel JR; Xiao KJ; Yang JC; Epling LB; Mukai K; Ye Q; Xu M; Qian D; Huo L; Weber M; Roman V; Lo Y; Drake K; Stump K; Covington M; Kapilashrami K; Zhang G; Ye M; Diamond S; Yeleswaram S; Macarron R; Deller MC; Wee S; Kim S; Wang X; Wu L; Yao W
J Med Chem; 2024 Feb; 67(4):3112-3126. PubMed ID: 38325398
[TBL] [Abstract][Full Text] [Related]
22. Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.
Freeman-Cook K; Hoffman RL; Miller N; Almaden J; Chionis J; Zhang Q; Eisele K; Liu C; Zhang C; Huser N; Nguyen L; Costa-Jones C; Niessen S; Carelli J; Lapek J; Weinrich SL; Wei P; McMillan E; Wilson E; Wang TS; McTigue M; Ferre RA; He YA; Ninkovic S; Behenna D; Tran KT; Sutton S; Nagata A; Ornelas MA; Kephart SE; Zehnder LR; Murray B; Xu M; Solowiej JE; Visswanathan R; Boras B; Looper D; Lee N; Bienkowska JR; Zhu Z; Kan Z; Ding Y; Mu XJ; Oderup C; Salek-Ardakani S; White MA; VanArsdale T; Dann SG
Cancer Cell; 2021 Oct; 39(10):1404-1421.e11. PubMed ID: 34520734
[TBL] [Abstract][Full Text] [Related]
23. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
Rao S; Lowe M; Herliczek TW; Keyomarsi K
Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
[TBL] [Abstract][Full Text] [Related]
24. MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2.
Gillam MP; Nimbalkar D; Sun L; Christov K; Ray D; Kaldis P; Liu X; Kiyokawa H
Oncogene; 2015 Feb; 34(7):932-8. PubMed ID: 24531709
[TBL] [Abstract][Full Text] [Related]
25. Hematopoiesis specific loss of Cdk2 and Cdk4 results in increased erythrocyte size and delayed platelet recovery following stress.
Jayapal SR; Wang CQ; Bisteau X; Caldez MJ; Lim S; Tergaonkar V; Osato M; Kaldis P
Haematologica; 2015 Apr; 100(4):431-8. PubMed ID: 25616574
[TBL] [Abstract][Full Text] [Related]
26. BC-N102 suppress breast cancer tumorigenesis by interfering with cell cycle regulatory proteins and hormonal signaling, and induction of time-course arrest of cell cycle at G1/G0 phase.
Lawal B; Kuo YC; Wu ATH; Huang HS
Int J Biol Sci; 2021; 17(12):3224-3238. PubMed ID: 34421361
[TBL] [Abstract][Full Text] [Related]
27. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
Prall OW; Sarcevic B; Musgrove EA; Watts CK; Sutherland RL
J Biol Chem; 1997 Apr; 272(16):10882-94. PubMed ID: 9099745
[TBL] [Abstract][Full Text] [Related]
28. Stress-mediated exit to quiescence restricted by increasing persistence in CDK4/6 activation.
Yang HW; Cappell SD; Jaimovich A; Liu C; Chung M; Daigh LH; Pack LR; Fan Y; Regot S; Covert M; Meyer T
Elife; 2020 Apr; 9():. PubMed ID: 32255427
[TBL] [Abstract][Full Text] [Related]
29. Study of a ligand complexed with Cdk2/Cdk4 by computer simulation.
Jiang Y; Zou J; Gui C
J Mol Model; 2005 Nov; 11(6):509-15. PubMed ID: 15928920
[TBL] [Abstract][Full Text] [Related]
30. The Role of CDK4/6 Inhibition in Breast Cancer.
Murphy CG; Dickler MN
Oncologist; 2015 May; 20(5):483-90. PubMed ID: 25876993
[TBL] [Abstract][Full Text] [Related]
31. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
32. Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 in hepatocytes inhibits DNA replication and liver regeneration in mice.
Hu W; Nevzorova YA; Haas U; Moro N; Sicinski P; Geng Y; Barbacid M; Trautwein C; Liedtke C
Hepatology; 2014 Feb; 59(2):651-60. PubMed ID: 23787781
[TBL] [Abstract][Full Text] [Related]
33. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
Jansen VM; Bhola NE; Bauer JA; Formisano L; Lee KM; Hutchinson KE; Witkiewicz AK; Moore PD; Estrada MV; Sánchez V; Ericsson PG; Sanders ME; Pohlmann PR; Pishvaian MJ; Riddle DA; Dugger TC; Wei W; Knudsen ES; Arteaga CL
Cancer Res; 2017 May; 77(9):2488-2499. PubMed ID: 28249908
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells.
Leontovich AA; Salisbury JL; Veroux M; Tallarita T; Billadeau D; McCubrey J; Ingle J; Galanis E; D'Assoro AB
Oncol Rep; 2013 May; 29(5):1785-8. PubMed ID: 23446853
[TBL] [Abstract][Full Text] [Related]
35. Temporal changes in cyclinD-CDK4/CDK6 and cyclinE-CDK2 pathways: implications for the mechanism of deficient decidualization in an immune-based mouse model of unexplained recurrent spontaneous abortion.
Chang Z; Kuang HX; Zhou X; Zhu H; Zhang Y; Fu Y; Fu Q; Jiang B; Wang W; Jiang S; Ren L; Ma L; Pan X; Feng XL
Mol Med; 2022 Sep; 28(1):100. PubMed ID: 36050637
[TBL] [Abstract][Full Text] [Related]
36. Role of Genetic Variations in
Híveš M; Jurečeková J; Kliment J; Grendár M; Kaplán P; Dušenka R; Evin D; Vilčková M; Holečková KH; Sivoňová MK
Cancer Genomics Proteomics; 2022; 19(3):362-371. PubMed ID: 35430569
[TBL] [Abstract][Full Text] [Related]
37. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Xi J; Ma CX
Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
[TBL] [Abstract][Full Text] [Related]
38. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
39. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
[TBL] [Abstract][Full Text] [Related]
40. Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells.
Adon AM; Zeng X; Harrison MK; Sannem S; Kiyokawa H; Kaldis P; Saavedra HI
Mol Cell Biol; 2010 Feb; 30(3):694-710. PubMed ID: 19933848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
